Actinium-225 in capsule
A new batch of accelerator-produced actinium-225 (Ac-225) will be available through the U.S. Department of Energy Isotope Program (DOE IP) in late September 2019. This alpha-emitting radionuclide and its decay product bismuth-213 (Bi-213), from an Ac-225/Bi-213 generator, have gained considerable interest within the medical community for their radioimmunotherapy applications.
The Ac-225 (half-life of 9.92 days) is produced at the DOE IP’s high-energy accelerators at both Los Alamos and Brookhaven National Laboratories through the proton bombardment of natural thorium targets, then separated and purified at Oak Ridge National Laboratory. Please visit the National Isotope Development Center’s product catalog to view product specifications and to request a quote.
The DOE IP routinely produces accelerator Ac-225 approximately every six weeks and will adjust batch frequency as needed to meet future market demand and ensure a reliable and abundant supply for research efforts and clinical trials.
For further inquiries about the availability of Ac-225, please contact the NIDC at email@example.com.